Emergent BioSolutions (EBS) Misses Q3 EPS by $2.71
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $5.81 +2.29%
EPS Growth %: -138.7%
Financial Fact:
Total revenues: 142.91M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -138.7%
Financial Fact:
Total revenues: 142.91M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of ($0.36), $2.71 worse than the analyst estimate of $2.35. Revenue for the quarter came in at $329 million versus the consensus estimate of $486.84 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle reports earnings today: AI spending bet faces its toughest test yet
- Bernstein SocGen on Cintas (CTAS): 'Setting up for a margin and EPS beat'
- 1-800-FLOWERS.Com (FLWS) Misses Q4 EPS by 10c, Misses on Revenue; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
